Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Cancer Prevention: A Message from the New Editors-in-Chief.

DuBois RN, Pollak MN.

Cancer Prev Res (Phila). 2019 Jan;12(1):1-2. doi: 10.1158/1940-6207.CAPR-18-0349. Epub 2018 Dec 27. No abstract available.

PMID:
30591430
2.

A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup.

Justice JN, Ferrucci L, Newman AB, Aroda VR, Bahnson JL, Divers J, Espeland MA, Marcovina S, Pollak MN, Kritchevsky SB, Barzilai N, Kuchel GA.

Geroscience. 2018 Dec;40(5-6):419-436. doi: 10.1007/s11357-018-0042-y. Epub 2018 Aug 27. Review.

3.

Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling.

Leuthold P, Schwab M, Hofmann U, Winter S, Rausch S, Pollak MN, Hennenlotter J, Bedke J, Schaeffeler E, Haag M.

J Proteome Res. 2018 Sep 7;17(9):3039-3049. doi: 10.1021/acs.jproteome.8b00199. Epub 2018 Aug 23.

PMID:
30091608
4.

Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer.

Wang Y, Nasiri AR, Damsky WE, Perry CJ, Zhang XM, Rabin-Court A, Pollak MN, Shulman GI, Perry RJ.

Cell Rep. 2018 Jul 3;24(1):47-55. doi: 10.1016/j.celrep.2018.06.008.

5.

Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.

Abrahami D, Yin H, Yu OHY, Pollak MN, Azoulay L.

Epidemiology. 2018 Mar;29(2):246-253. doi: 10.1097/EDE.0000000000000793.

PMID:
29283894
6.

Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women.

Alemán JO, Iyengar NM, Walker JM, Milne GL, Da Rosa JC, Liang Y, Giri DD, Zhou XK, Pollak MN, Hudis CA, Breslow JL, Holt PR, Dannenberg AJ.

J Endocr Soc. 2017 Apr 25;1(6):625-637. doi: 10.1210/js.2017-00020. eCollection 2017 Jun 1.

7.

Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women.

Farland LV, Mu F, Eliassen AH, Hankinson SE, Tworoger SS, Barbieri RL, Dowsett M, Pollak MN, Missmer SA.

Cancer Causes Control. 2017 Dec;28(12):1441-1452. doi: 10.1007/s10552-017-0971-2. Epub 2017 Oct 31.

8.

Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study.

Sanders JL, Guo W, O'Meara ES, Kaplan RC, Pollak MN, Bartz TM, Newman AB, Fried LP, Cappola AR.

J Gerontol A Biol Sci Med Sci. 2018 Jun 14;73(7):953-959. doi: 10.1093/gerona/glx143.

9.

Circulating resistin levels and risk of multiple myeloma in three prospective cohorts.

Santo L, Teras LR, Giles GG, Weinstein SJ, Albanes D, Wang Y, Pfeiffer RM, Lan Q, Rothman N, Birmann BM, Colditz GA, Pollak MN, Purdue MP, Hofmann JN.

Br J Cancer. 2017 Oct 10;117(8):1241-1245. doi: 10.1038/bjc.2017.282. Epub 2017 Aug 22.

10.

Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease.

Hofmann JN, Mailankody S, Korde N, Wang Y, Tageja N, Costello R, Zingone A, Hultcrantz M, Pollak MN, Purdue MP, Landgren O.

Obesity (Silver Spring). 2017 Aug;25(8):1317-1320. doi: 10.1002/oby.21894. Epub 2017 Jun 11.

11.

Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial.

Liao LM, Hofmann JN, Cho E, Pollak MN, Chow WH, Purdue MP.

Cancer Causes Control. 2017 Jul;28(7):801-807. doi: 10.1007/s10552-017-0901-3. Epub 2017 May 8.

12.

Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis.

Pollak MN.

Nat Rev Clin Oncol. 2017 May;14(5):268. doi: 10.1038/nrclinonc.2017.57. Epub 2017 Apr 19. No abstract available.

PMID:
28422114
13.

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.

Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA.

Ann Oncol. 2017 Jul 1;28(7):1560-1568. doi: 10.1093/annonc/mdx152.

14.

Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?

Klil-Drori AJ, Azoulay L, Pollak MN.

Nat Rev Clin Oncol. 2017 Feb;14(2):85-99. doi: 10.1038/nrclinonc.2016.120. Epub 2016 Aug 9. Review.

PMID:
27502359
15.
16.

Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms.

Babic A, Bao Y, Qian ZR, Yuan C, Giovannucci EL, Aschard H, Kraft P, Amundadottir LT, Stolzenberg-Solomon R, Morales-Oyarvide V, Ng K, Stampfer MJ, Ogino S, Buring JE, Sesso HD, Gaziano JM, Rifai N, Pollak MN, Anderson ML, Cochrane BB, Luo J, Manson JE, Fuchs CS, Wolpin BM.

Cancer Res. 2016 Dec 15;76(24):7160-7167. Epub 2016 Oct 25.

17.

Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits.

Teumer A, Qi Q, Nethander M, Aschard H, Bandinelli S, Beekman M, Berndt SI, Bidlingmaier M, Broer L; CHARGE Longevity Working Group, Cappola A, Ceda GP, Chanock S, Chen MH, Chen TC, Chen YD, Chung J, Del Greco Miglianico F, Eriksson J, Ferrucci L, Friedrich N, Gnewuch C, Goodarzi MO, Grarup N, Guo T, Hammer E, Hayes RB, Hicks AA, Hofman A, Houwing-Duistermaat JJ, Hu F, Hunter DJ, Husemoen LL, Isaacs A, Jacobs KB, Janssen JA, Jansson JO, Jehmlich N, Johnson S, Juul A, Karlsson M, Kilpelainen TO, Kovacs P, Kraft P, Li C, Linneberg A, Liu Y, Loos RJ; Body Composition Genetics Consortium, Lorentzon M, Lu Y, Maggio M, Magi R, Meigs J, Mellström D, Nauck M, Newman AB, Pollak MN, Pramstaller PP, Prokopenko I, Psaty BM, Reincke M, Rimm EB, Rotter JI, Saint Pierre A, Schurmann C, Seshadri S, Sjögren K, Slagboom PE, Strickler HD, Stumvoll M, Suh Y, Sun Q, Zhang C, Svensson J, Tanaka T, Tare A, Tönjes A, Uh HW, van Duijn CM, van Heemst D, Vandenput L, Vasan RS, Völker U, Willems SM, Ohlsson C, Wallaschofski H, Kaplan RC.

Aging Cell. 2016 Oct;15(5):811-24. doi: 10.1111/acel.12490. Epub 2016 Jun 21. Erratum in: Aging Cell. 2017 Aug;16(4):898.

18.

Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.

Lian Y, Yin H, Pollak MN, Carrier S, Platt RW, Suissa S, Azoulay L.

Eur Urol. 2016 Nov;70(5):808-815. doi: 10.1016/j.eururo.2016.04.035. Epub 2016 May 10.

PMID:
27178449
19.

Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.

Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN.

Breast Cancer Res Treat. 2016 May;157(1):101-8. doi: 10.1007/s10549-016-3806-z. Epub 2016 Apr 26.

PMID:
27116182
20.

Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals.

Hofmann JN, Birmann BM, Teras LR, Pfeiffer RM, Wang Y, Albanes D, Baris D, Colditz GA, De Roos AJ, Giles GG, Hosgood HD, Lan Q, Landgren O, Liao LM, Rothman N, Weinstein SJ, Pollak MN, Neuhouser ML, Purdue MP.

Cancer Res. 2016 Apr 1;76(7):1935-41. doi: 10.1158/0008-5472.CAN-15-2406. Epub 2016 Feb 26.

21.

Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.

Inamura K, Song M, Jung S, Nishihara R, Yamauchi M, Lochhead P, Qian ZR, Kim SA, Mima K, Sukawa Y, Masuda A, Imamura Y, Zhang X, Pollak MN, Mantzoros CS, Harris CC, Giovannucci E, Fuchs CS, Cho E, Chan AT, Wu K, Ogino S.

J Natl Cancer Inst. 2015 Nov 23;108(4). pii: djv363. doi: 10.1093/jnci/djv363. Print 2016 Apr.

22.

Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.

Chapman JA, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN.

Breast Cancer Res Treat. 2015 Sep;153(2):353-60. doi: 10.1007/s10549-015-3547-4. Epub 2015 Aug 15.

23.

A prospective study of insulin-like growth factor 1, its binding protein 3, and risk of endometriosis.

Mu F, Hankinson SE, Schernhammer E, Pollak MN, Missmer SA.

Am J Epidemiol. 2015 Jul 15;182(2):148-56. doi: 10.1093/aje/kwv037. Epub 2015 Jun 28.

24.

Similarity of Serum and Plasma Insulin-like Growth Factor Concentrations.

Houghton LC, Pollak MN, Tao Y, Tu YG, Black A, Bradwin G, Hoover RN, Troisi R.

Biomark Cancer. 2015 Jun 8;7:13-7. doi: 10.4137/BIC.S23088. eCollection 2015.

25.

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW.

Lancet Oncol. 2015 Jul;16(7):839-47. doi: 10.1016/S1470-2045(15)00027-3. Epub 2015 Jun 8.

PMID:
26067687
26.

Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.

Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN, Hursting SD.

Diabetes. 2015 May;64(5):1632-42. doi: 10.2337/db14-1132. Epub 2015 Jan 9.

27.

Competing risks of death in younger and older postmenopausal breast cancer patients.

Chapman JA, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN.

World J Clin Oncol. 2014 Dec 10;5(5):1088-96. doi: 10.5306/wjco.v5.i5.1088.

28.

The use of aspirin and the risk of mortality in patients with prostate cancer.

Assayag J, Pollak MN, Azoulay L.

J Urol. 2015 Apr;193(4):1220-5. doi: 10.1016/j.juro.2014.11.018. Epub 2014 Nov 14.

PMID:
25463991
29.

Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, Kenfield SA, Stampfer MJ, Giovannucci EL.

Int J Cancer. 2015 May 15;136(10):2418-26. doi: 10.1002/ijc.29295. Epub 2014 Nov 10.

30.

Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development.

Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BM.

Nat Med. 2014 Oct;20(10):1193-1198. doi: 10.1038/nm.3686. Epub 2014 Sep 28.

31.

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN.

Breast Cancer Res Treat. 2014 Nov;148(1):81-90. doi: 10.1007/s10549-014-3141-1. Epub 2014 Sep 25.

32.

Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer.

Assayag J, Pollak MN, Azoulay L.

Eur J Cancer. 2014 Nov;50(16):2838-45. doi: 10.1016/j.ejca.2014.08.006. Epub 2014 Sep 6.

PMID:
25204805
33.

Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria.

Bridges HR, Jones AJ, Pollak MN, Hirst J.

Biochem J. 2014 Sep 15;462(3):475-87. doi: 10.1042/BJ20140620.

34.

The use of metformin in patients with prostate cancer and the risk of death.

Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2111-8. doi: 10.1158/1055-9965.EPI-14-0056. Epub 2014 Jul 13.

35.

Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study.

Lai GY, Giovannucci EL, Pollak MN, Peskoe SB, Stampfer MJ, Willett WC, Platz EA.

Cancer Causes Control. 2014 May;25(5):625-32. doi: 10.1007/s10552-014-0369-3. Epub 2014 Mar 25.

36.

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.

de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN.

Clin Cancer Res. 2014 Apr 1;20(7):1925-34. doi: 10.1158/1078-0432.CCR-13-1869. Epub 2014 Feb 17.

37.

Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.

Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, Pollak MN, Chambers AF.

Breast Cancer Res. 2014 Jan 22;16(1):R8. doi: 10.1186/bcr3600.

38.

Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada).

Borugian MJ, Spinelli JJ, Gordon PB, Abanto Z, Brooks-Wilson A, Pollak MN, Warren LJ, Hislop TG, Gallagher RP.

Cancer Causes Control. 2014 Mar;25(3):385-94. doi: 10.1007/s10552-014-0339-9. Epub 2014 Jan 17.

PMID:
24435933
39.

Type 2 diabetes and the risk of mortality among patients with prostate cancer.

Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L.

Cancer Causes Control. 2014 Mar;25(3):329-38. doi: 10.1007/s10552-013-0334-6. Epub 2014 Jan 3.

PMID:
24384808
40.

Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.

Friedbichler K, Hofmann MH, Kroez M, Ostermann E, Lamche HR, Koessl C, Borges E, Pollak MN, Adolf G, Adam PJ.

Mol Cancer Ther. 2014 Feb;13(2):399-409. doi: 10.1158/1535-7163.MCT-13-0598. Epub 2013 Dec 2.

41.

Plasma C-peptide, mammographic breast density, and risk of invasive breast cancer.

Ahern TP, Hankinson SE, Willett WC, Pollak MN, Eliassen AH, Tamimi RM.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1786-96. doi: 10.1158/1055-9965.EPI-13-0375.

42.

Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.

Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. doi: 10.1158/1055-9965.EPI-13-0349. Epub 2013 Aug 27.

43.

The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus.

Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1877-83. doi: 10.1158/1055-9965.EPI-13-0196. Epub 2013 Aug 21.

44.

Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer.

Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, Cochrane BB, Pollak MN, Manson JE, Giovannucci EL, Fuchs CS.

J Natl Cancer Inst. 2013 Jul 17;105(14):1027-35. doi: 10.1093/jnci/djt123. Epub 2013 Jul 11.

45.

Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.

Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente L, Blenis J, Pollak MN, Olumi AF, Vander Heiden MG, Stephanopoulos G.

Cancer Res. 2013 Jul 15;73(14):4429-38. doi: 10.1158/0008-5472.CAN-13-0080. Epub 2013 May 17.

46.

Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer.

Assayag J, Yin H, Benayoun S, Pollak MN, Suissa S, Azoulay L.

Cancer Causes Control. 2013 May;24(5):839-45. doi: 10.1007/s10552-012-0132-6. Epub 2013 Apr 2.

PMID:
23546609
47.

Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation.

Moiseeva O, Deschênes-Simard X, St-Germain E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN, Ferbeyre G.

Aging Cell. 2013 Jun;12(3):489-98. doi: 10.1111/acel.12075. Epub 2013 Apr 23.

48.

Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts.

Bao Y, Giovannucci EL, Kraft P, Qian ZR, Wu C, Ogino S, Gaziano JM, Stampfer MJ, Ma J, Buring JE, Sesso HD, Lee IM, Rifai N, Pollak MN, Jiao L, Lessin L, Cochrane BB, Manson JE, Fuchs CS, Wolpin BM.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):855-61. doi: 10.1158/1055-9965.EPI-12-1458. Epub 2013 Mar 5.

49.

A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts.

Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, Rifai N, Pollak MN, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM.

J Natl Cancer Inst. 2013 Jan 16;105(2):95-103. doi: 10.1093/jnci/djs474. Epub 2012 Dec 14.

50.

Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin.

Zakikhani M, Bazile M, Hashemi S, Javeshghani S, Avizonis D, St Pierre J, Pollak MN.

PLoS One. 2012;7(11):e49513. doi: 10.1371/journal.pone.0049513. Epub 2012 Nov 21.

Supplemental Content

Loading ...
Support Center